<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 8.5: Senolytic Dosing Strategies: The 'Hit and Run' Approach</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/PURPLE theme for Longevity/Senescence */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #3b82f6;
        }

        .term-item .term {
            font-weight: 700;
            color: #1e3a8a;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs & Lists */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .content-list {
            font-size: 17px;
            margin: 20px 0;
            padding-left: 24px;
        }

        .content-list li {
            margin-bottom: 14px;
            line-height: 1.7;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #daeaff 60%);
            padding: 0 4px;
            font-weight: 600;
            color: #1e3a8a;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Comparison Table */
        .data-table-container {
            overflow-x: auto;
            margin: 35px 0;
            border-radius: 12px;
            border: 1px solid #e5e5e5;
        }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        .data-table th {
            background: #f1f5f9;
            padding: 15px;
            color: #1e3a8a;
            font-weight: 700;
            border-bottom: 2px solid #e2e8f0;
        }

        .data-table td {
            padding: 15px;
            border-bottom: 1px solid #f1f5f9;
            color: #444;
        }

        .data-table tr:last-child td {
            border-bottom: none;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .check-understanding .box-label {
            font-weight: 600;
            color: #8B6914;
            margin: 0 0 24px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
            position: relative;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #1e3a8a;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #eff6ff;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px;
            margin-top: 35px;
            border-radius: 12px;
            border: 1px solid #cbd5e1;
        }

        .takeaways-box .box-label {
            font-weight: 700;
            color: #1e3a8a;
            margin-bottom: 15px;
            text-transform: uppercase;
            font-size: 14px;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #fafafa;
            border-radius: 12px;
            border: 1px solid #eee;
            font-size: 14px;
        }

        .references-box h4 {
            margin: 0 0 15px 0;
            color: #666;
            font-size: 15px;
        }

        .ref-list {
            list-style: none;
            padding: 0;
            margin: 0;
        }

        .ref-list li {
            margin-bottom: 8px;
            color: #777;
            line-height: 1.5;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.9;
        }

        .lesson-footer .brand {
            color: #1e3a8a;
            font-weight: 600;
            font-size: 15px;
        }

        @media (max-width: 768px) {
            .toc-list { grid-template-columns: 1fr; }
            .stats-grid { grid-template-columns: repeat(2, 1fr); }
            .lesson-container { padding: 20px 15px; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 8: Senescent Cell Management (S)</p>
            <h1 class="lesson-title">Lesson 8.5: Senolytic Dosing Strategies: The 'Hit and Run' Approach</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 5 of 8</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Biological Rationale</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Continuous vs. Intermittent Dosing</a></li>
                <li><a href="#section3"><span class="section-num">3</span>The 'Hit and Run' Protocol</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Agent-Specific Strategies</a></li>
                <li><a href="#section5"><span class="section-num">5</span>Monitoring & Biomarkers</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Safety & Contraindications</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define the 'Hit and Run' dosing methodology and its importance in senolytic therapy.</li>
                <li>Explain why intermittent dosing is superior to chronic dosing for cellular longevity.</li>
                <li>Identify the specific cycles used in clinical research for Dasatinib, Quercetin, and Fisetin.</li>
                <li>Analyze the safety implications of clearing senescent cells vs. inhibiting their signaling.</li>
                <li>Develop a framework for assessing client readiness for senolytic interventions.</li>
            </ul>
        </div>

        <h2 id="section1">The Biological Rationale: Why Intermittent?</h2>
        <p>In traditional pharmacology, most drugs require a "steady state" concentration in the blood to remain effective. For example, blood pressure medication or insulin must be present constantly to manage symptoms. However, senolytics operate under a fundamentally different paradigm. We are not managing a symptom; we are <span class="highlight">pruning a population</span>.</p>

        <p>Senescent cells do not divide. Once a senolytic agent triggers apoptosis (programmed cell death) in a "zombie cell," that specific cell is permanently removed. It takes weeks, months, or even years for a new population of senescent cells to accumulate through further DNA damage or metabolic stress. Therefore, constant exposure to senolytic agents is not only unnecessary but potentially counterproductive.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">48h</div>
                    <div class="stat-label">Max Exposure Needed</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">6-12wk</div>
                    <div class="stat-label">Re-accumulation Time</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">30%</div>
                    <div class="stat-label">Reduction in SASP</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">0.1%</div>
                    <div class="stat-label">Cells Needing Removal</div>
                </div>
            </div>
        </div>

        <p>A 2015 seminal study by Kirkland et al. demonstrated that a single brief course of senolytics could improve vasomotor function and reduce frailty in aged mice for several months. This led to the development of the <span class="highlight">V.I.T.A.L.S. Method‚Ñ¢</span> focus on "Senescent Cell Management," emphasizing that "less is more" when it comes to the frequency of intervention.</p>

        <h2 id="section2">Continuous vs. Intermittent Dosing</h2>
        <p>Understanding the difference between senolytics (cell killers) and senomorphics (SASP inhibitors) is critical for dosing. Senomorphics often require chronic administration to keep inflammation suppressed. Senolytics, however, thrive on the 'Hit and Run' approach.</p>

        <div class="data-table-container">
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Continuous Dosing</th>
                        <th>'Hit and Run' (Intermittent)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Primary Goal</strong></td>
                        <td>Maintain blood concentration</td>
                        <td>Trigger acute apoptosis threshold</td>
                    </tr>
                    <tr>
                        <td><strong>Toxicity Risk</strong></td>
                        <td>High (cumulative organ stress)</td>
                        <td>Low (brief exposure window)</td>
                    </tr>
                    <tr>
                        <td><strong>Off-Target Effects</strong></td>
                        <td>May inhibit healthy cell function</td>
                        <td>Spares healthy cells due to timing</td>
                    </tr>
                    <tr>
                        <td><strong>Resistance</strong></td>
                        <td>Cells may adapt to drug presence</td>
                        <td>Avoids cellular adaptation</td>
                    </tr>
                    <tr>
                        <td><strong>Wound Healing</strong></td>
                        <td>May impair (senescence is needed for repair)</td>
                        <td>Preserves acute healing capacity</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">The 'Hit and Run' Protocol: The 2-Day Cycle</h2>
        <p>The standard 'Hit and Run' protocol established in clinical trials (such as those conducted at the Mayo Clinic) typically involves a <span class="highlight">pulse dosing schedule</span>. The agent is administered for 2 to 3 consecutive days, followed by a "washout period" of 14 to 30 days.</p>

        <p>Why two days? Research indicates that the pro-survival pathways (SCAPs) used by senescent cells to evade death are most effectively disrupted with a 48-hour window of inhibition. Beyond 72 hours, the risk of affecting non-senescent stem cells or causing gastrointestinal distress increases significantly without providing additional senolytic benefit.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë§</div>
                <div>
                    <p class="box-label">Case Study: Metabolic Rejuvenation</p>
                    <p style="color:rgba(255,255,255,0.8); margin:0; font-size:13px;">Client: Robert, 64 | Goal: Reduce Systemic Inflammaging</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">R</div>
                    <div class="patient-info">
                        <h4>Robert H.</h4>
                        <p>High hs-CRP (3.8 mg/L), chronic joint stiffness, and fasting glucose of 108 mg/dL.</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> Robert was guided through a "Hit and Run" protocol using Fisetin (20mg/kg body weight) for 2 consecutive days, repeated monthly for 3 months.</p>
                <p><strong>Outcomes:</strong>
                    <ul>
                        <li>hs-CRP dropped from 3.8 to 1.4 mg/L (63% reduction).</li>
                        <li>Self-reported "morning stiffness" decreased by 40% on the WOMAC scale.</li>
                        <li>No adverse effects reported during the "off" weeks.</li>
                    </ul>
                </p>
            </div>
        </div>

        <h2 id="section4">Agent-Specific Strategies</h2>
        <p>Not all senolytics are dosed the same. The chemical half-life and the specific SCAP pathways targeted dictate the strategy. As a coach, understanding these nuances allows you to help clients navigate the complexity of their longevity protocols.</p>

        <div class="principle-card">
            <p class="principle-title">Dasatinib + Quercetin (D+Q)</p>
            <p class="principle-text">This is the most potent combination. Dasatinib (a tyrosine kinase inhibitor) and Quercetin (a flavonoid) target multiple senescent cell types, including adipocytes and endothelial cells.</p>
            <ul>
                <li><strong>Clinical Protocol:</strong> 100mg D + 1000mg Q for 2 days.</li>
                <li><strong>Frequency:</strong> Once every 30-90 days.</li>
                <li><strong>Note:</strong> Requires medical supervision as Dasatinib is a prescription medication.</li>
            </ul>
        </div>

        <div class="principle-card">
            <p class="principle-title">High-Dose Fisetin</p>
            <p class="principle-text">Fisetin is a natural senolytic found in strawberries. It is particularly effective against senescent immune cells (T-cells) and fat cells.</p>
            <ul>
                <li><strong>The Mayo Protocol:</strong> ~20mg per kg of body weight.</li>
                <li><strong>Schedule:</strong> 2 days on, 28 days off.</li>
                <li><strong>Bioavailability:</strong> Best taken with a fat-containing meal to enhance absorption.</li>
            </ul>
        </div>

        <h2 id="section5">Monitoring & Biomarkers of Success</h2>
        <p>How do we know the 'Hit and Run' worked? Unlike weight loss, the results of senescent cell clearance are often microscopic before they become macroscopic. We look for changes in the <span class="highlight">SASP (Senescence-Associated Secretory Phenotype)</span>.</p>

        <p>Key biomarkers to monitor include:</p>
        <ul class="content-list">
            <li><strong>hs-CRP:</strong> A general marker of systemic inflammation. Reductions often follow successful clearance.</li>
            <li><strong>Interleukin-6 (IL-6):</strong> A primary cytokine of the SASP. High levels are associated with frailty.</li>
            <li><strong>GDF15:</strong> Emerging as a highly sensitive marker of cellular stress and senescence burden.</li>
            <li><strong>Clinical Observations:</strong> Improved grip strength, faster walking speed, and reduced joint pain are the primary "functional" markers used in the V.I.T.A.L.S. Method‚Ñ¢.</li>
        </ul>

        <h2 id="section6">Safety & Contraindications</h2>
        <p>While the 'Hit and Run' approach minimizes risk, senolytics are not for everyone. Senescence is a natural process that serves specific biological needs, particularly in <span class="highlight">acute wound healing</span> and tumor suppression (in its early stages).</p>

        <div class="alert-box warning">
            <p class="alert-label">‚ö†Ô∏è Practitioner Caution</p>
            <p>Senolytics should be avoided in the following scenarios:
                <br>1. <strong>Post-Surgery:</strong> Senescent cells are required for the first 48-72 hours of wound closure.
                <br>2. <strong>Pregnancy/Lactation:</strong> The effects on fetal development are unknown.
                <br>3. <strong>Acute Infection:</strong> The immune system may use transient senescence to control viral replication.
            </p>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            
            <div class="question-item">
                <span class="question-number">1</span>
                <p class="question-text">Why is constant (daily) dosing of senolytics considered suboptimal compared to the 'Hit and Run' approach?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    Constant dosing increases the risk of cumulative toxicity and may interfere with necessary biological processes like wound healing. Since senescent cells take weeks to re-accumulate, a brief "hit" is sufficient to clear the current burden without the side effects of chronic exposure.
                </div>
            </div>

            <div class="question-item">
                <span class="question-number">2</span>
                <p class="question-text">According to the Mayo Clinic protocol for Fisetin, what is the recommended dosing duration and frequency?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    The protocol typically involves high-dose administration (approx. 20mg/kg) for 2 consecutive days, followed by a 28-day (one month) washout period.
                </div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>The 'Hit and Run' approach uses brief, high-dose pulses to trigger apoptosis in senescent cells while sparing healthy ones.</li>
                <li>Senolytics do not require a steady-state blood concentration because they remove the source of inflammation permanently.</li>
                <li>The 2-day cycle is the research gold standard for agents like D+Q and Fisetin.</li>
                <li>Coaches must monitor the SASP (via IL-6 or hs-CRP) to evaluate the efficacy of the intervention.</li>
                <li>Timing is crucial; senolytics should never be used during active wound healing or recovery from major surgery.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="ref-list">
                <li>Kirkland, J. L., & Tchkonia, T. (2020). "Senolytic drugs: from discovery to translation." Journal of Internal Medicine.</li>
                <li>Xu, M. et al. (2018). "Senolytics improve physical function and increase lifespan in old age." Nature Medicine.</li>
                <li>Verdoorn, B. P. et al. (2021). "Fisetin as a Senolytic: A Review of Clinical Evidence." Mayo Clinic Proceedings.</li>
                <li>Justice, J. N. et al. (2019). "Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study." EBioMedicine.</li>
                <li>Niedernhofer, L. J., & Robbins, P. D. (2018). "Senolytics: A new weapon in the anti-aging arsenal." Medical Clinics of North America.</li>
                <li>Chaib, S. et al. (2022). "Cellular senescence and senolytics: The path to the clinic." Nature Medicine.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy | Anti-Aging & Longevity Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. The V.I.T.A.L.S. Method‚Ñ¢ is a proprietary framework.</p>
        </footer>
    </div>
</body>

</html>